Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 301–400 of 647
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., & Schlosser, M. (2025) · PLOS ONE · doi:10.1371/journal.pone.0310160 · Cited by 6
“Never-theless, recent systematic reviews and meta-analyses suggest that both meditation practice and psychedelic use may be beneficial for a range of psychological symptoms [11–15].”
Dleštíková, T. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103900 · Cited by 7
MDMA for the treatment of misophonia, a proposal
Webb, J., & Keane, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.983285 · Cited by 7
Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies
Santos, G. H. D. M., Rodrigues, L. S., Rocha, J. M., Rossi, G. N., Oña, G., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2023) · Psychoactives · doi:10.3390/psychoactives2010006 · Cited by 9
“Nevertheless, the use of psilocybin for the treatment of major depression and treatment-resistant major depression was designated a breakthrough therapy by the United States Food and Drug Administration in 2019, demonstrating the scientific community’s recognition of the possible usefulness of this class of substances…”
BackgroundCritical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021012 · Cited by 11
Psychedelic drugs as new tools in psychiatric therapeutics
Schenberg, E. E. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0012 · Cited by 6
Chovan, J. D. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197559321.003.0050 · Cited by 6
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., & Schlosser, M. (2024) · doi:10.1101/2024.08.27.24312677 · Cited by 6
Downey, A. E., Bradley, E., Lerche, A. S., O’Donovan, A., Krystal, A. D., & Woolley, J. D. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0051 · Cited by 6
An initiative for living evidence synthesis in clinical psychedelic research
Singleton, S. P., Sevchik, B. L., Vandekar, S., Strain, E. C., Nayak, S. M., Dworkin, R. H., Scott, J. C., & Satterthwaite, T. D. (2025) · Nature Mental Health · doi:10.1038/s44220-024-00373-4 · Cited by 4
Psilocybin has a narrow therapeutic window as an antidepressant treatment
Seillier, L., Čechová, B., Seillier, A., & Šlamberová, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111368 · Cited by 6
Garel, N., Plourde, L., Greenway, K. T., & Dorval, M. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00446-y · Cited by 5
Psychiatric Residents’ Perspectives on Psychedelics and Psychedelic Assisted Therapy
Barnett, B. S., Arakelian, M. H., Weleff, J., Squier-Roper, T., King, F., Cumming, D., & Falcone, T. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2527296 · Cited by 6
Ludbrook, G., Bryson, N., Taylor, B., Hocevar‐Trnka, J., Johnson, M. W., Hirman, J., Morrish, G. A., Alexander, R., & Pollack, M. H. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002047 · Cited by 5
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
Newer Treatments for Mood and Anxiety Disorders
Markman, J., & Combs, H. L. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.006 · Cited by 5
McMillan, R. M., Reynolds, J., & Fernandez, A. V. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2433522 · Cited by 6
“Psychedelic therapy is a therapeutic approach that involves using psychedelic compounds alongside psychotherapy (Reiff et al., 2020).”
Majić, T., Schmidt, T. T., Gröticke, A., Gasser, P., Richards, W. A., Riemer, T., & Evens, R. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251326937 · Cited by 7
“In addition, psychedelics have been proposed for treating certain mental health conditions (Reiff et al., 2020), such as treatment-resistant depression (Carhart-Harris et al., 2021; Goodwin et al., 2022), substance-use disorders (Bogenschutz et al., 2022), and depression and anxiety in patients…”
Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces
Suay, D., Aicher, H., Kometer, M., Mueller, M. J., Caflisch, L., Hempe, A., Steinhart, C. P., Elsner, C., Wicki, I. A., Müller, J., et al. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121247 · Cited by 6
What are set and setting: Reducing vagueness to improve research and clinical practice
Patch, K., & Smith, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337372 · Cited by 8
“Second, psychedelics have positive outcomes in placebo-controlled trials—though admittedly blinding is difficult to ensure in psychedelic trials (Aday et al., 2022; Reiff et al., 2020).”
Chao, Y., & Horton, J. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.90 · Cited by 9
Psychedelics: Their Limited Understanding and Future in the Treatment of Chronic Pain
Hedau, V. N., & Anjankar, A. P. (2022) · Cureus · doi:10.7759/cureus.28413 · Cited by 8
“Recent studies found that psychedelic-assisted therapy can effectively treat pain and mental health disorders [6].”
BackgroundAbrams, S. K., Rabinovitch, B. S., Zafar, R. R., Aziz, A. S., Cherup, N. P., McMillan, D. W., Nielson, J. L., & Lewis, E. C. (2023) · Neurotrauma Reports · doi:10.1089/neur.2023.0022 · Cited by 7
Sepehry, A. A., Schultz, I. Z., Mallinson, A. I., & Longridge, N. S. (2024) · Psychological Injury and Law · doi:10.1007/s12207-024-09506-7 · Cited by 7
“…et al., 2019) as a novel add-on therapy for anxiety and depression, it would be only a matter of time for a patient with depression/anxiety-related vestibular dysfunction to try such treatment modalities, either as polyp-harmacy or in combination with psychotherapeutic methods (Reiff et al., 2020).”
Berlowitz, I., Torres, E. G., Ruiz-Macedo, J. C., Wolf, U., Maake, C., & Martin-Soelch, C. (2024) · Health Education & Behavior · doi:10.1177/10901981231213348 · Cited by 1
“…“breakthrough therapies” by the FDA (Butler et al., 2020; Carhart-Harris et al., 2021; Chi & Gold, 2020; dos Santos & Hallak, 2021; Fisher et al., 2021; Kyzar et al., 2017; Luoma et al., 2020; Nichols, 2020; Nichols et al., 2017; Reiff et al., 2020; Siegel et al., 2021; Vermetten & Yehuda, 2020).”
Combinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 6
“…psychiatry has also led to studies illustrating the improved benefits of psychedelic-assisted psychotherapy for social anxiety in ASD, PTSD, anxiety, and depression when compared with psychotherapy alone [209,210]; similar approaches have also enhanced the results of group psychotherapy [211,212].”
Meditative in-action: an endogenous epistemic venturePreprint
Pagnoni, G., & Guareschi, F. T. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/mdbgq · Cited by 10
Evolutionary Perspective on Improving Mental Health
Grinde, B. (2022) · Encyclopedia · doi:10.3390/encyclopedia2030099 · Cited by 4
“Psychedelic substances, such as ketamine and psilocybin, offer a novel form of medication [90].”
BackgroundMason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2022) · medRxiv · doi:10.1101/2022.10.31.22281688 · Cited by 5
Pogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.01.543310 · Cited by 5
Koolen, M. H. B., Wirsching, A., Krediet, E., & van Elk, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2508156 · Cited by 6
Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review
Moreno‐Chaparro, J., Castañeda-Millán, G., & Eslava-Schmalbach, J. H. (2025) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000653 · Cited by 4
Obi, T., & Ressler, K. J. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02371-9 · Cited by 7
In naturalistic psychedelic use, group use is common and acceptable
Byrne, K., Lindsay, S., Baker, N. J., Schmutz, C., & Lewis, B. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00261 · Cited by 6
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
Development of the Japanese version of the Challenging Experience Questionnaire
Tani, H., Yonezawa, K., Kusudo, K., Barrett, F. S., Nakajima, S., & Uchida, H. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12456 · Cited by 3
A review on advanced formulations strategies to prevent prescription drug abuse and their impact
Chandegra, B., Raval, J., & Prajapati, P. (2024) · Discover Medicine · doi:10.1007/s44337-024-00141-4 · Cited by 4
Salvinorin A and Salvia divinorum: Toxicology, Pharmacological Profile, and Therapeutic Potential
Calado, S., Pires, B., Rosendo, L. M., Rosado, T., Gallardo, E., & Duarte, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125588 · Cited by 4
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 5
Schipper, S., Nigam, K. B., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015383 · Cited by 5
Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review
Moret, R. M., Sanz‐Gómez, S., Gascón, S., & Alacreu‐Crespo, A. (2024) · Psychoactives · doi:10.3390/psychoactives3030021 · Cited by 4
“Regarding the psychological pathways, it has been proposed that psilocybin enhances cognitive flexibility [168] and reduces feelings of social exclusion [169].”
BackgroundBarber, M., Gardner, J., Liknaitzky, P., & Carter, A. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12545 · Cited by 6
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Gold, N. D., Pagni, B. A., Petridis, P. D., & Bogenschutz, M. P. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0030 · Cited by 4
Psychedelika in der Psychiatrie: eine offene Debatte
Herwig, U., Schnell, K., Daumann, J., Jungaberle, A., Koller, G., Mertens, L. J., & Borgwardt, S. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2453-0910 · Cited by 4
“Im Kontext der psychotherapeutischen Nutzung einer psycho aktiven Wirkung gibt es neben den Psychedelika weitere Substan zen [1].”
InfluentialPerspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
Kinahan, S. P., & Wilson, E. J. (2025) · Counselling and Psychotherapy Research · doi:10.1002/capr.12881 · Cited by 5
Sznitman, S. R., Behar, Y. A., Dicker‐Oren, S. D., Shochat, T., Meiri, D., Butto, N., Roe, D., & Bernstein, A. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06704-8 · Cited by 8
“Empirically, ayahuasca research is relatively modest in scope and rigor relative to certain other psychedelics (e.g. psilocybin) (Reiff et al. 2020; Aday et al. 2021; Golden et al. 2022; Bender and Hellerstein 2022).”
Inducing Effects of Illegal Drugs to Improve Mental Health by Self-Regulation Therapy: A Pilot Study
Amigó, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910387 · Cited by 7
A case report of posttraumatic stress disorder at the end of life
Riss, T. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00892-0 · Cited by 4
“and Drug Administration (FDA) as “breakthrough therapies” [19].”
BackgroundAltman, B. R., Earleywine, M., & Leo, J. A. D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2020382 · Cited by 4
Žuljević, M. F., Viđak, M., Vukojević, J., Hren, D., & Peričić, T. P. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015345 · Cited by 5
Psychedelics for Alzheimer's Disease Palliative Care
McManus, K. R., Patrick, R. E., Striepe, M. I., Drury, M. J., Ozonsi, R., Forester, B. P., & Weinberg, M. S. (2022) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2022.06.001 · Cited by 5
The Evolving Role of History in the Past, Present, and Future of Psychedelic Patenting
Shams, S., Pratt, A. R., Li, S., & Isenbarger, T. (2023) · History of Pharmacy and Pharmaceuticals · doi:10.3368/hopp.65.1.117 · Cited by 6
Liblik, S. A., da Cunha, T. R., Liblik, C. S. D. F. K., Biscioni, D. N., & Girardi, D. R. (2024) · Salud Colectiva · doi:10.18294/sc.2024.4630 · Cited by 8
Garcia, A. C. M., Maia, L. O., & Reed, P. G. (2024) · Journal of Holistic Nursing · doi:10.1177/08980101241257836 · Cited by 9
“With the expiration of Sandoz ’ s last patents for the production of LSD in 1963, illicit production of this substance and its use outside of healthcare contexts signi fi cantly increased (Hofmann, 2009; Reiff et al., 2020).”
Psychedelic therapies and belief change: are there risks of epistemic harm or epistemic injustice?
Zeller, M. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2362284 · Cited by 6
“(5) Conducting rigorous research to further elucidate the mechanisms, efficacy, and safety of PAPs, and to refine best practices for clinical application (Reiff et al., 2020).”
Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy
Fusco, A. F., Olowofela, B. O., Dagra, A., Hatem, R., Pierre, K., Siyanaki, M. R. H., & Lucke-Wold, B. P. (2022) · MedPress Psychiatry and Behavioral Sciences · doi:10.33582/mppbs.2022.202209003 · Cited by 3
Thomas, K. L. H., Jesse, R., Mehtani, N. J., Mitchell, J., & Anderson, B. T. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2201244 · Cited by 4
“…dose, when combined with psychosocial support, has been found to improve mood symptoms, anxiety, substance use outcomes, as well as inducing persisting beneficial changes in personality structure and prosocial behaviors in a number of early phase trials (Griffiths et al. 2018; Reiff et al. 2020).”
BackgroundGaur, P., Engel, L. B., Hall, D. R., Khoo, C., Sarris, J. J., Perkins, D., Li, C. G., & Low, M. (2025) · Forensic Chemistry · doi:10.1016/j.forc.2025.100659 · Cited by 3
Cioe, P. A., Stang, G. S., Azam, D., & Dugal, S. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00563-0 · Cited by 4
“Psilocybin-assisted treatment has been referred to as “breakthrough therapy” by the US Food & Drug Administration [23].”
McHerron, D., Barber, M., Ham, R., Liknaitzky, P., Carter, A., & Gardner, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251377191 · Cited by 4
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
“109,110 These effects occur through novel biochemical pathways unutilised by current PTSD treatments and represent an opportunity to address limitations of current pharmacological treatment paradigms.”
AI-generated virtual psychedelics bridge digital and therapeutic frontiers in mental health research
Riva, G., Brizzi, G., Rastelli, C., & Greco, A. (2026) · Nature Mental Health · doi:10.1038/s44220-025-00576-3 · Cited by 4
Prevalence and Correlates of Past-Year Psilocybin Use in the United States
Yang, K. H., Eun, A., & Palamar, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251343 · Cited by 5
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
“159 Additionally, some psyche-delics such as LSD and mescaline have acute effects that can last up to 12 h or longer and therefore pose practical issues to their study in outpatient clinical trials.”
Dendritogenic Potential of the Ethanol Extract from Lippia alba Leaves in Rat Cortical Neurons
Toledo, M. M. V., Lattig, M. C., Chitiva, L. C., Costa, G. M., Sutachan, J. J., & Albarracín, S. L. (2023) · Molecules · doi:10.3390/molecules28186666 · Cited by 3
“Several recent studies have shown this secondary metabolite’s great potential for treating a wide spectrum of mood disorders, including treatment-resistant depression [19,20,23–25].”
BackgroundBeyond prohibition: A public health analysis of naturalistic psychedelic use
Haden, M., Paschall, S. A., & Woods, B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00450 · Cited by 6
Äbelö, A., Smallridge, J. W., von Rotz, R., Dornbierer, D., Egger, K., Ashton, M., & Scheidegger, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118329 · Cited by 6
Žuljević, M. F., Viđak, M., Vukojević, J., Hren, D., & Peričić, T. P. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00369-6 · Cited by 3
“On 16 August 2017, the FDA granted an expedited drug development pathway, the breakthrough therapy des-ignation for MDMA-AP in the treatment of PTSD [18].”
Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry
Kalin, N. H. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030290 · Cited by 4
Self-citationPsychedelics for treating psychiatric disorders: Are they safe?
Thakur, M. (2022) · Current Psychiatry · doi:10.12788/cp.0309 · Cited by 4
Opening Death’s Door: Psilocybin and Existential Suffering in Palliative Care
Waring, D. R. (2023) · Philosophy and medicine · doi:10.1007/978-3-031-12692-5_13 · Cited by 5
Educational Materials and Image Induction Increase Treatment Credibility
Low, F., & Earleywine, M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2154722 · Cited by 3
“The PAT description also drew on published data (Davis et al. 2021; Johnson et al. 2014; Reiff et al. 2020; Schenberg 2018), and emphasized the neurological action of psilocybin on the serotonergic system as well as the effects of mystical experiences, the rapid onset of symptom relief, and the…”
MethodNeurobiologie und Wirkmodelle zu Psychedelika
Herwig, U., Avram, M., Borgwardt, S., & Aicher, H. (2024) · Nervenheilkunde · doi:10.1055/a-2261-0745 · Cited by 3
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
A bibliometric analysis of research on psychedelics for depression treatment
Hua, H., Fu, X., Wang, W., Wang, S., Wang, D., Wu, Z., Zhang, Q., He, T., & Yang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36886 · Cited by 3
“While many literature reviews have provided comprehensive and detailed descriptions of the treatment of depression with psychedelic drugs [32 – 34], a high-quality bibliometric study on this topic is still needed.”
BackgroundEmmerich, N. (2024) · Neuroethics · doi:10.1007/s12152-024-09571-4 · Cited by 3
“At pre-sent, scientifically establishing the therapeutic value of psychedelics in general—and Psychedelic Assisted Psychotherapy (PAP) 1 in particular—continues to be the primary aim [13].”
Interventional Psychiatry in India: Bridging Treatment Gaps and Expanding Horizons in Mental Health
Joseph, J. T., & Praharaj, S. K. (2024) · Indian Journal of Psychological Medicine · doi:10.1177/02537176241294146 · Cited by 4
De-Mystifying Mysticism: A Critical Realist Perspective on Ambivalences in the Study of Mysticism
Qadir, A., & Tiaynen-Qadir, T. (2024) · Religions · doi:10.3390/rel16010010 · Cited by 7
“One line of studies covers mystical senses in guided psychedelic use (Barrett and Griffiths 2017; Griffiths et al. 2018; Johnson et al. 2019; Reiff et al. 2020).”
Tunstad, P. A., Kvam, T.-M., Uthaug, M. V., Stewart, L. H., Andersen, K. A. A., & Grønnerød, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556299 · Cited by 4
Jensen, A. A., Cecchi, C. R., Hibicke, M., Bach, A. H., Kaadt, E., Märcher-Rørsted, E., Nichols, C. D., Elfving, B., & Kristensen, J. L. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00208 · Cited by 4
MDMA-assisted psychotherapy for the treatment of PTSD
Reiff, C. M., & McDonald, W. M. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0020 · Cited by 3
Self-citationAltered states phenomena induced by visual flicker light stimulationPreprint
Bartossek, M. T., Kemmerer, J., & Schmidt, T. T. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/825nc · Cited by 4
Gordon, A. R., Carrithers, B. M., Pagni, B. A., Kettner, H., Marrocu, A., Nayak, S. M., Weiss, B., Carhart-Harris, R. L., Roberts, D. E., & Zeifman, R. J. (2024) · Research Square · doi:10.21203/rs.3.rs-4203641/v1 · Cited by 5
Fitzgerald, P. B., Webb, S. L., Denning, N. C., Dowie, T.-I., Schweickle, M. M., Modak, A., Chan, G., Knight, J., Waldron, M., Gainsford, K., et al. (2025) · medRxiv · doi:10.1101/2025.05.28.25328532 · Cited by 3
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Psychedelics and cognitive function: A systematic review
Cardoso, C. G., & Viana, M. D. B. (2023) · Research Society and Development · doi:10.33448/rsd-v12i14.44436 · Cited by 3
Chaudhry, S., Weisman, A., Hagen, M. M., Pauli, K. L. S., & Tabaac, B. J. (2024) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2024.2398456 · Cited by 3
“…a therapeutic role of psychedelics in conditions including anxiety, depression, alcohol use, tobacco use, post-traumatic stress disorder (PTSD), and hospice care (Mithoefer et al. 2016; Ross et al. 2016; Luoma et al. 2020; Reiff et al. 2020; Davis et al. 2021; Maia et al. 2022; Holze et al. 2023).”
BackgroundAicher, H., Wicki, I. A., Meling, D., Mueller, M. J., Dornbierer, D., & Scheidegger, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251344689 · Cited by 3
“Several systematic reviews and meta-analyses have been conducted, showing the promising potential of psychedelic-assisted therapies (Andersen et al., 2021; Ko et al., 2023; Luoma et al., 2020; Reiff et al., 2020; Romeo et al., 2021).”
McMillan, R. M., Fowler, J. A., Erbacher, T., Ireland, R. E. E., Brown, S. J., Brömdal, A., Wang, G., & Mullens, A. B. (2025) · Journal of Homosexuality · doi:10.1080/00918369.2025.2526046 · Cited by 2
Sabé, M., Seragnoli, F., Thorens, G., ZULLINO, D. F., Sentissi, O., Solmi, M., Böge, K., Kaiser, S., & Kirschner, M. (2025) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.250005 · Cited by 2
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Bilenker, D., & Avena, N. M. (2025) · Brain Sciences · doi:10.3390/brainsci15080893 · Cited by 2
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes
Kishon, R., & Cycowicz, Y. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1637162 · Cited by 3
“According to PAT, in the preparatory phase, therapists work with patients to explore their background, help them understand their symptoms and treatment goals, and establish a strong therapeutic rapport (46).”
Intersections of Psychedelics, Mystical Experiences, and Hypnosis
Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2554387 · Cited by 2
“However, we are arguably experiencing a “psychedelic renaissance” (Reiff et al., 2020) in which there has been an exponential increase in interest, research, and use of psychedelic substances.”
Driscoll, B., & Lakhan, S. E. (2025) · Psychoactives · doi:10.3390/psychoactives4040035 · Cited by 2
“The last two decades have seen a significant resurgence of clinical and scientific interest in psychedelic-assisted therapy for a range of psychiatric conditions, including depression, post-traumatic stress disorder (PTSD), anxiety, and substance use disorders [1,2].”
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 4
Brown, R. E., Lissemore, J. I., Shinozuka, K., Coetzee, J. P., Faerman, A., Olash, C., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120722 · Cited by 4
Syed, O. A., Nestor, S. M., Husain, M. I., Sinyor, M., Alam, F., & Giacobbe, P. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116929 · Cited by 2
Moshfeghinia, R., Mostafavi, S., Jazi, K., Ghasemi, A. R., Khosravani-Nezhad, Y., Narayanan, S., Ahmadi, J., & Pasalar, M. (2026) · BMC Psychology · doi:10.1186/s40359-025-03935-y · Cited by 4
“Psi-locybin (4-phosphoryloxy-N, N-dimethyltryptamine), commonly known as “magic mushrooms,” is a natural tryptamine/indoleamine compound with a long history of traditional use and a favorable safety profile [1–3].”
Kaczmarek, E. S., Rodrigues, N. B., Chisamore, N., Doyle, Z., Meshkat, S., Blainey, M. G., Brudner, R. M., Ali, S., Teopiz, K. M., McIntyre, R. S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121385 · Cited by 3
Fares‐Otero, N. E., Furukawa, Y., Sijbrandij, M., Leucht, S., Vieta, E., Cuijpers, P. J., Harrer, M., & Seedat, S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112802 · Cited by 2
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.